StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Zithromax (azithromycin) — Worldwide revenues by Year

Zithromax (azithromycin) — Worldwide revenues ($M) ($M)

Pfizer Zithromax (azithromycin) — Worldwide revenues: $399M in FY2025, down 16.9% from a year earlier.

Latest, FY2025
399
Period ended Dec 31, 2025
Change on a year earlier
-16.9%
480 in FY2024
History
10 years
Since FY2016
Sources
9
Documents cited below

Where the FY2025 figure comes from

“|| Zithromax | 399 | 480 | (17%) | (16%) | — | 1 | (66%) | 399 | 479 | (17%) | (16%)”

Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗

Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Breakdown

What makes up zithromax (azithromycin) — Worldwide revenues

Cite this data

StockData. (2026). Pfizer Zithromax (azithromycin) — Worldwide revenues ($M), annual FY2016–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/zithromax-ww

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.